Inclisiran as a siRNA Inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9); Past, Present, and Future

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Molecular Biology

Background:

• Elevated low-density lipoprotein cholesterol (LDL-C) is a primary risk factor for atherosclerotic cardiovascular disease (ASCVD).
• Statins are the primary therapy for LDL-C reduction, but alternative treatments are needed for patients with statin intolerance or suboptimal response.
• The discovery of proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway's role in LDL-C regulation opened new therapeutic targets.

Purpose of the Study:

• To review the clinical evidence supporting inclisiran, a small interfering ribonucleic acid (siRNA) therapy targeting PCSK9.
• To analyze the efficacy and safety of inclisiran in reducing LDL-C levels.
• To discuss ongoing research and future directions in PCSK9 inhibition therapies.

Main Methods:

• Review of Phase 3 clinical trials (ORION-9, ORION-10, ORION-11) evaluating inclisiran.
• Analysis of data on LDL-C reduction, safety, and tolerability.
• Examination of scientific literature on PCSK9 biology and therapeutic strategies.

Main Results:

• Inclisiran demonstrated significant LDL-C reductions across trials: 39.7% (ORION-9), 52.3% (ORION-10), and 49.9% (ORION-11).
• Inclisiran offers a novel therapeutic option for LDL-C management, particularly for patients requiring additional lipid-lowering strategies.
• The drug targets PCSK9, a key regulator of LDL receptor degradation.

Conclusions:

• Inclisiran represents a significant advancement in LDL-C lowering therapy, offering a new mechanism of action via PCSK9 inhibition.
• The established efficacy and safety profile support its role in managing hypercholesterolemia and reducing ASCVD risk.
• Further research into PCSK9 inhibition continues to evolve, promising new treatments for cardiovascular disease.